Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccine

Seattle-based biotech company HDT Bio raised $3 million in seed funding to support work on its COVID-19 vaccine candidate that uses a cutting-edge, replicating RNA approach. The new funding will allow HDT Bio to add staff who have experience in clinical disease trials. The company is hoping to start a clinical trial of the vaccine in human volunteers in Brazil this October, with subsequent trials in the U.S. and India potentially launching in November. Read the story at GeekWire »